DXCM Dexcom Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$89.75

Market cap

$33.87B

P/E Ratio

34.65

Dividend/share

N/A

EPS

$2.59

Enterprise value

$34.11B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 96

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. ...

Highlights
The EPS has soared by 79% YoY and by 8% QoQ
Dexcom's net income has soared by 75% YoY and by 7% from the previous quarter
The stock's price to earnings (P/E) is 62% less than its 5-year quarterly average of 92.0 but 16% more than its last 4 quarters average of 29.9
The quick ratio has declined by 14% since the previous quarter but it has grown by 5% year-on-year
The company's equity fell by 11% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.dexcom.com
Peers: EW WST BDX TNDM

Key stats

What are the main financial stats of DXCM

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
-1.89%
1 week
5.9%
1 month
21.09%
1 year
12.24%
YTD
35.23%
QTD
33.26%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$4.97B
Gross profit
$3.1B
Operating income
$1.14B
Net income
$999.7M
Gross margin
62.5%
Net margin
20.1%
Dexcom's net income has soared by 75% YoY and by 7% from the previous quarter
DXCM's operating income has surged by 66% year-on-year and by 10% since the previous quarter
The net margin has soared by 51% YoY and by 4.1% from the previous quarter
The operating margin has increased by 43% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does DXCM's price correlate with its fundamentals

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
DXCM P/E details
P/E
34.65
P/B
13.21
P/S
6.9
EV/EBIT
26.27
EV/EBITDA
21.83
EV/Sales
6.86
The EPS has soared by 79% YoY and by 8% QoQ
The stock's price to earnings (P/E) is 62% less than its 5-year quarterly average of 92.0 but 16% more than its last 4 quarters average of 29.9
DXCM's P/B is 42% above its last 4 quarters average of 9.3 but 22% below its 5-year quarterly average of 17.0
The company's equity fell by 11% QoQ
The stock's price to sales (P/S) is 40% less than its 5-year quarterly average of 11.5 but 28% more than its last 4 quarters average of 5.4
Dexcom's revenue has increased by 16% YoY and by 3.1% from the previous quarter

Efficiency

How efficient is Dexcom business performance
DXCM's return on invested capital has surged by 100% year-on-year and by 13% since the previous quarter
Dexcom's ROA has soared by 74% YoY and by 10% from the previous quarter
The ROE is up by 41% year-on-year and by 7% since the previous quarter
The ROS rose by 40% YoY and by 2.8% QoQ

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 68% higher than its total liabilities
The total liabilities has declined by 19% year-on-year but it has increased by 4.3% since the previous quarter
Dexcom's current ratio has increased by 14% YoY but it has decreased by 11% QoQ
The debt is 49% less than the equity
DXCM's debt to equity is down by 48% YoY but it is up by 13% QoQ
The debt has decreased by 47% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.